{"entity":{"id":"nct05918445","kind":"trial","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of PM8002 in advanced solid tumours, run by Biotheus Inc., now recruiting.","summary":"PM8002 in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05918445 by Biotheus Inc., with 380 participants planned, started 2021-03-09 and due to reach its primary completion in 2025-11-30. Interventions recorded: PM8002.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05918445","url":"https://clinicaltrials.gov/study/NCT05918445"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002"],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05918445","phase":"1/2","setting":"Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Biotheus Inc.","enrolled":380,"outcomes":[]},"route":"/trials/nct05918445/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}